CTMX - CytomX Therapeutics Inc

CTMX - CytomX Therapeutics Inc

https://www.cytomx.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

CytomX Therapeutics ( CTMX ) Reports Break-Even Earnings for Q2

Zacks Commentary • 1 month, 1 week ago • score: 0.16

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +100.00% and +2.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

This CytomX Therapeutics Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday - Cisco Systems ( NASDAQ:CSCO ) , CAE ( NYSE:CAE )

Benzinga • 4 months ago • score: 0.41

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report - CytomX Therapeutics ( NASDAQ:CTMX )

Benzinga • 4 months ago • score: 0.14

A 43% partial response rate was observed in a 10 mg/kg cohort of CX-2051-treated colorectal cancer patients. CytomX raised $100 million from a stock offering and extended its cash runway into Q2 2026. Don't miss this list of 10 overlooked stocks-including one paying a 9% dividend-before Wall ...

CytomX Therapeutics ( CTMX ) Beats Q1 Earnings and Revenue Estimates

Zacks Commentary • 4 months ago • score: 0.07

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 50% and 43.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.

52W High

$3.10

52W Low

$0.40

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.18

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

4.56

Forward P/E (<15 better)

14.20

EV/EBITDA (<8 favorable)

5.03

EV/Revenue (<3 favorable)

1.59

P/S (TTM) (<3 favorable)

2.67

P/B (<3 favorable)

3.14

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.79%

Institutions (25–75% balanced)

89.61%

Shares Outstanding

164,913,000

Float

120,279,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

141,100,000

Gross Profit (TTM)

141,100,000

EPS (TTM)

0.50

Profit Margin (>10% good)

0.34%

Operating Margin (TTM) (higher better)

-0.07%

ROE (TTM) (>15% strong)

1.08%

EPS YoY (Quarterly) (>10% good)

0.61

Revenue YoY (Quarterly) (>8% good)

-0.26

Momentum

Bearish momentum

Value

-0.0239

Previous

-0.0137

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025